Sulpiride and refractory panic disorder

  title={Sulpiride and refractory panic disorder},
  author={Emerson Arcoverde Nunes and Rafael Christophe Freire and M. Reis and Adriana Cardoso de Oliveira e Silva and Sergio Machado and Jos{\'e} Alexandre S. Crippa and Serdar M. Dursun and Glen B. Baker and Jaime E.C. Hallak and Ant{\^o}nio Eg{\'i}dio Nardi},
Dear Editor, The use of antipsychotics in patients with anxiety in recent years has increased, with a recent study showing that over a 12-year period, antipsychotic prescriptions in visits for anxiety disorders increased from 10.6 to 21.3 %, with the biggest increase among panic disorder (PD) patients (from 8 to 21.3 %) (Comer et al. 2011). Reasons for this remain unclear, but possible explanations include changes in patient characteristics, including increasing severity of illnesses among… 



National trends in the antipsychotic treatment of psychiatric outpatients with anxiety disorders.

Although little is known about their effectiveness for anxiety disorders, antipsychotic medications are becoming increasingly prescribed to psychiatric outpatients with these disorders.

Management of treatment-resistant panic disorder.

The current understanding of the pathophysiology of PD using a "fear circuit" model is highlighted and a differential diagnostic approach for clinical evaluation of unsatisfactory response to treatment in PD is presented.


Despite the daunting title, thi5 latest in the admirable 'Mind and Medicine' series is almost as read' able as it is instructive. What is psychopharmacology Not, or anyway not only, as I ha<j vaguely

Antidepressant action of sulpiride. Results of a placebo-controlled double-blind trial.

This trial proved that sulpiride is effective and well-tolerated when given in a mean dose of 181 mg per day for mild and moderate depression.

Dopamine D1 and D2 receptor ligands modulate the behaviour of mice in the elevated plus-maze

Aripiprazole Augmentation in Major Depressive Disorder: A Double-Blind, Placebo-Controlled Study in Patients with Inadequate Response to Antidepressants

This is the third consecutive clinical trial to demonstrate that aripiprazole augmentation to antidepressants is an efficacious and well-tolerated treatment for patients with MDD who do not respond adequately to standard antidepressant monotherapy.

The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.

The Mini-International Neuropsychiatric Interview is designed to meet the need for a short but accurate structured psychiatric interview for multicenter clinical trials and epidemiology studies and to be used as a first step in outcome tracking in nonresearch clinical settings.

l-Sulpiride, at a low, non-neuroleptic dose, prevents conditioned fear stress-induced freezing behavior in rats

It is demonstrated that long-term administration of low, non-neuroleptic doses of l-sulpiride, is highly effective in an animal model of anticipatory anxiety/panic behavior.